



MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Corporate Identity No. L24111UR1986PLC015895

Regd. Office: Upper Kesalton, Tallital, Nainital- 263 001, Uttarakhand, Tel: 9871862796

*W: www.mescopharma.com E-mail: nsparameswaran@mescosteel.com

MPL/33/QTR-2/2019-20

14th November, 2019

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

Scrip ID: MESPHER-B

Scrip Code: 500274

Sub: Un-Audited Financial Results for the Quarter ended 30th September, 2019

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Un-Audited Financial Results for the Quarter ended 30th September, 2019.

M/s. Sangram Paul & Co., Chartered Accountants, Statutory Auditors of the Company has issued the Limited Review Report

The Board meeting commenced at 03:00 P.M. and concluded at 04:00 P.M.

A Copy of the said results together with Limited Review Report is enclosed herewith. These results are also being made available on the website of the Company at [http: www.mescopharma.com](http://www.mescopharma.com)

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mesco Pharmaceuticals Limited**

Company Secretary

Nurani Shankar Parameswaran
Company Secretary cum Compliance Officer

Sangram Paul & Co.

S.K.Paul. F.C.A

Chartered Accountant

Chartered Accountants

Plot No.-754/15, Jayadev Vihar, Bhubaneswar-751 013

Phone : 0674-2360863, Mob. : 9337116878

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

**To the Board of Directors of
Mesco Pharmaceutical Limited**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **MESCO PHARMACEUTICALS LIMITED** ("the Company"), for the quarter and six months ended 30th September, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sangram Paul & Co.

Chartered Accountants

Firm Registration No. 308001E

UDIN: 19013015AAAAAS6312

S.K. Paul

Proprietor

M. No.: - 013015

Date: 14th November, 2019

Place: Bhubaneswar



MESCO PHARMACEUTICALS LTD

CIN : L24111UR1986PLC015895

REGD.OFFICE : UPPER KESALTON, TALLITAL, NAINITAL-263 001, UTTARAKHAND

Tel. :011-41587085, E-mail : nsparameswaran@mescosteel.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2019

(In Rs.)

Sl No	PARTICULARS	Quarter Ended			Half Year Ended		Year Ended
		30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
		UNAUDITED	AUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Income from Operations						
	(a) Net Sales/ Income from operations	-	-	-	-	-	-
	(b) Other Income	-	-	-	-	-	-
	Total Income from Operations (net)	-	-	-	-	-	-
2	Expenses						
	(a) Cost of Material Consumed	-	-	-	-	-	-
	(b) Change in Inventories of finished goods and work in progress	-	-	-	-	-	-
	(c) Employees Benefits Expenses	-	-	-	-	-	-
	(d) Depreciation and Amortisation expenses	-	-	-	-	-	-
	(e) Finance Cost	-	-	-	-	-	-
	(f) Other Expenses	110,728	854,355	3,571,752	965,083	3,870,952	4,098,033
	Total Expenses	110,728	854,355	3,571,752	965,083	3,870,952	4,098,033
3	Profit/(Loss) Before Exceptional items and Tax	(110,728)	(854,355)	(3,571,752)	(965,083)	(3,870,952)	(4,098,033)
	Finance Costs & Exceptional Items (1-2)						
	Exceptional Items	-	-	-	-	-	-
4	Profit/(Loss) before Tax	(110,728)	(854,355)	(3,571,752)	(965,083)	(3,870,952)	(4,098,033)
	(a) Current Tax	-	-	-	-	-	-
	(b) Deferred Tax	-	-	-	-	-	-
	(c) Tax expense relating to Earlier years	-	-	-	-	-	-
7	Profit for the Period	(110,728)	(854,355)	(3,571,752)	(965,083)	(3,870,952)	(4,098,033)
	Other Comprehensive Income						
	If any	-	-	-	-	-	-
	Total Comprehensive Income for the Period	(110,728)	(854,355)	(3,571,752)	(965,083)	(3,870,952)	(4,098,033)
14	Paid up Equity Share Capital	197,381,000	197,381,000	197,381,000	197,381,000	197,381,000	197,381,000
	(Face value Rs.10/- per Equity Share)						
16	Earning per share (before and after extraordinary items) (Rs.10- each)						
	Basic (Rs.)	(0.01)	(0.04)	(0.18)	(0.05)	(0.19)	(0.20)
	Diluted (Rs.)	(0.01)	(0.04)	(0.18)	(0.05)	(0.19)	(0.20)

Notes :

- The above Results, have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective Board Meeting held on **14.11.19**
- The Statutory Auditors of the Company have carried out Limited Review of the above Results.
- Figures for the previous period have been re-classified, re-grouped/ re-arranged wherever necessary.
- There were no manufacturing activities in the company during the period under consideration

Date: 14.11.2019

Place: New Delhi

For MESCO PHARMACEUTICALS LIMITED

Sameer Singh
SAMEER SINGH

Managing Director

DIN: 06862254

STATEMENT OF ASSETS AND LIABILITIES

(In Rs.)

	As at 30.09.2019 (Unaudited)	As at 31.03.2019 (audited)
ASSETS		
Non-current assets		
Property, plant and equipment	1,798,761.00	1,798,761.00
Capital work-in-progress	-	-
Investment Property	-	-
Non-current investments	1.00	285,000.00
Financial assets	-	-
Security deposit	-	-
Other financial assets	-	-
Other Non Current Assets	-	-
Current assets		
Inventories	-	-
Financial assets :	-	-
Trade receivables	-	-
Cash and cash equivalents	395,918.00	395,918.00
Loans	-	-
Other financial assets	-	-
Prepayments	-	-
	2,194,680.00	2,479,679.00
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share capital	197,381,000.00	197,381,000.00
(b) Other Equity		
Capital Reserve	-	-
Securities Premium	-	-
Treasury Shares	-	-
Retained Earnings	(307,495,108.00)	(306,530,025.00)
Reserve representing unrealised gains/losses	-	-
General Reserve	-	-
Other reserve	-	-
Total Equity	(110,114,108.00)	(109,149,025.00)
Non-current liabilities		
Financial liabilities:		
Borrowings	112,171,568.00	111,392,716.00
Trade Payables	-	-
Other Financial Liability	-	-
Deferred tax liabilities (net)	-	-
Other Non-Current liabilities	-	-
Current liabilities		
Short-term borrowings	-	-
Financial liabilities:		
Trade payables	136,576.00	228,300.00
Other Financial Liability	-	-
Other payables	-	-
Provisions	644.00	7,688.00
	2,194,680.00	2,479,679.00

LIMITED

SAMEER SINGH

MANAGING DIRECTOR

DIN: 06862254

PLACE : NEW DELHI

DATED : 14.11.2019

Mesco Pharmaceuticals Limited Unaudited Cash Flow Statement for the period ended September 30, 2019 (Figures in Rs.)			
	Particulars	For the period ended 30th Sept, 2019	For the year ended 31st March, 2019
A.	<u>Cash Flow from Operating Activities</u>		
	Item	(965,083)	(4,098,033)
	Adjustments for:		
	Impairment Loss	284,999	-
	Amortisation and Write off	-	-
	changes	(680,084)	(4,098,033)
	Working Capital changes:		
	Trade receivables	-	-
	Short term loans and advances	-	-
	Short Term Provisions	(7,044)	7,256
	Trade payable	(91,724)	157,301
	Other current assets		1,800
	Cash generated from operations	(778,852)	(3,931,676)
	Direct Taxes Paid	-	-
	Net Cash from operating activities	(778,852)	(3,931,676)
B.	<u>Cash Flow from Investing Activities</u>		
	Change in Non-current investments	-	-
	Loans & Advances	-	-
	Interest on deposits	-	-
	Net Cash from investing activities	-	-
C.	<u>Cash Flow from Financing Activities</u>		
	Proceeds from issue of Share Capital	-	-
	Payment to Borrowings	778,852	-
	Proceeds from Loans and advances	-	3,931,677
	Net cash from financing activities	778,852	3,931,677
	Net change in cash & cash equivalent (A+B+C)	-	1
	Cash & Cash equivalents opening balance	395,918	395,917
	Cash & Cash Equivalents at the End of the Year	395,918	395,918

Date: 14.11.2019

Place: New Delhi

For MESCO PHARMACEUTICALS LIMITED


SAMEER SINGH

Managing Director

DIN: 06862254